Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice-yearly lenacapavir versus daily oral PrEP for HIV prevention in young gay, trans, and non-binary people in Brazil
RBR-10qp94n8Recruiting
- Sponsor
- Evandro Chagas National Institute of Infectology
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenacapavir, tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Evandro Chagas National Institute of Infectology. Started Aug 2025; status: recruiting.
02
Drugs
lenacapavirtenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on RBR-10qp94n8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-10qp94n8.